Embera NeuroTherapeutics
Sudbury
About Embera NeuroTherapeutics
Embera NeuroTherapeutics is a development stage pharmaceutical company focused on developing treatments for smoking cessation and other addictions, for which there are a limited range of effective drug therapies or have no approved treatments. Embera is developing a novel addiction treatment (EMB-001) that targets specific and complementary brain functions that drive the craving and relapse associated with these disorders, an approach based on breakthrough discoveries of the scientific founder.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $28.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2021)
- Website: emberaneuro.com
- Phone: +1 (318) 213-0198
Industries & Categories
Addiction Treatment, Biotechnology, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/embera-neurotherapeutics-95813 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.